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Pulmonary function testsAbstract Aim of the work: To assess obstructive sleep apnea (OSA) as one of the common
primary sleep disorders in patients with rheumatoid arthritis (RA) and study its correlation to
disease activity and pulmonary function tests.
Patients and methods: This study included 30 female patients with RA who fulﬁlled the
American College of Rheumatology/European league against rheumatism classiﬁcation criteria.
All the patients were subjected to full medical history, thorough clinical examination with
evaluation of the disease activity using disease activity score-28 (DAS28), laboratory assessment
of highly sensitive C-reactive protein (hsCRP), pulmonary function tests (PFTs) (FVC, FEV1
and FEV1/FVC) and one night polysomnography at the sleep laboratory.
Results: Polysomnographic data revealed OSA in 14 RA patients (46.7%). Patients with OSA
showed longer disease duration (7.0 ± 1.94 years), higher BMI (30.8 ± 2.48), hsCRP level (6.7
± 0.6 mg/L) and DAS28 (4.9 ± 1.85) than patients with no OSA (4.0 ± 1.72 years, 20.3 ± 1.55,
4.9 ± 0.3 mg/L and 3.7 ± 1.28 respectively). There was non-signiﬁcant difference between both
groups regarding the PFTs (p> 0.05). The study showed a signiﬁcant correlation between AHI
(apnea-hypopnea index) and BMI, hsCRP and DAS28 (r= 0.45, 0.43 and 0.51, respectively)
(p< 0.05). No signiﬁcant correlation was detected between AHI and PFTs.
Conclusion: Obstructive sleep apnea is commonly associated with RA patients; these ﬁndings
possibly suggest common underlying pathological mechanisms which may be linked to chronic
166 N. Fouda, A.A. Dayeminﬂammation. Co-existence of OSA in RA patients may inﬂuence the disease activity and the level
of circulating inﬂammatory markers. Considering diagnosis and treatment of this sleep disorder in
RA patients may help in improved clinical care, better prognosis and avoid rheumatoid-associated
morbidities.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is a chronic, inﬂammatory disease
that is characterized by joint pain and swelling and can lead to
disability and functional limitations [1,2]. In addition, more
than half of patients with RA report sleep disturbance, a rate
of prevalence that is 2–3 times greater than that found in the
general population [3]. Such disturbed sleep may be due to
pain, depression, lack of exercise, or corticosteroid usage [4].
Cross-sectional studies have found that sleep disturbance
correlates with greater pain and disease activity [5]. It is often
thought that difﬁculties with sleep are due to RA-related pain.
However, sleep disturbance and pain may be bidirectionally
related [6]. Sleep dysfunction and primary sleep disorders are
increasingly recognized in people with RA [7]. The morbidity
and mortality which may be associated with untreated sleep
disorders, particularly obstructive sleep apnea (OSA), raise
the priority of this aspect of patient care [8].
Obstructive sleep apnea (OSA) is a signiﬁcant public health
concern and contributes to increased cardiovascular morbidity
and mortality [9]. It is deﬁned by the American Academy of
Sleep Medicine [10] as repetitive episodes of upper airway
obstruction occurring during sleep and usually associated with
a reduction in oxygen saturation [11]. Symptoms of concern
include sleep episodes during wakefulness, daytime sleepiness,
unrefreshing sleep, fatigue, insomnia, waking up breath hold-
ing, gasping or choking and loud snoring [12].
Diagnosis of obstructive sleep apnea can be indicated by
symptomatology and the presence of known risk factors as
increasing age, obesity and large neck circumference, although
OSA can occur in individuals with none of these risk factors
[13]. Also a number of tools and methods are available for
the assessment of sleep health as self-reported questionnaire
instruments [14]. However, the gold standard for diagnosis
of OSA is the overnight polysomnography (PSG) [15].
The aim of the work was to assess obstructive sleep apnea
(OSA) as one of common primary sleep disorders in patients
with rheumatoid arthritis (RA) and study its correlation to
disease activity and pulmonary function tests.
2. Patients and methods
The present study is a cross sectional one that included 30
female patients with RA, fulﬁlling the American College of
Rheumatology/European league against rheumatism (ACR/
EULAR) criteria for classiﬁcation of RA [16]. They were
selected from patients attending the Rheumatology and
Rehabilitation outpatient clinic in Ain Shams University
Hospitals (ASUH).
All the patients were on a stable disease-modifying drug
regimen for three months prior to study entry. The study
was approved by the local ethics committee and writtenconsent was obtained from all patients after a full explanation
of the study.
2.1. Exclusion criteria
– Patients on anti-tumor necrosis factor (TNF) or corticoste-
roid therapy.
– Patients on sedative or hypnotic drugs or with history of
withdrawal of stimulants as coffee or tobacco.
– Patients with abnormalities in soft palate or upper airway.
– Pregnancy.
2.2. Clinical assessment
– Full history taking was performed laying stress on disease
duration and symptoms suggestive of OSA e.g. day-time
sleep, somnolence, morning headache, fatigue, waking up,
breath holding, gasping or choking and loud snoring.
– Local examination of the chest, ear, nose and throat was
carried-out.
– The BMI (kg/m2) was determined by weight (kg) and height
(m) (Quelet index).
– The disease activity was assessed using disease activity score
28 (DAS28) [17]. Patients with DAS28 score 62.6 were con-
sidered in remission [18].
2.3. Laboratory assessment
– Complete blood picture was assessed using coulter counter.
– Rheumatoid factor (RF) was evaluated by enzyme-linked
immunosorbent assay (ELISA).
– Erythrocyte sedimentation rate (ESR) was determined
using Westergren Blot method.
– Highly sensitive C-reactive protein (hsCRP) concentration
was measured using a latex-particle enhanced turbidimetric
immunoassay [19]. Samples of peripheral venous blood
were collected and stored at 80 C until the time of assay.2.4. Pulmonary function tests
The tests were done in the pulmonary laboratory. The best of 3
measures obtained while the patient is breathing room air by
ﬂow volume spirometry (Flow mate model 2500) were used
to calculate the following parameters:
– Forced vital capacity (FVC): amount of air that can be
forcefully expelled from maximally inﬂated lung.
– Forced expiratory volume in 1st second (FEV-1): Volume
of air expelled during the ﬁrst second of FVC.
– Ratio of FEV-1 to FVC (FEV-1/FVC).
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The test was done in sleep laboratory in chest department in
ASUH using the Somnomedic (Germany) system. The patient
arrived about two hours before bed time without having made
any changes in daily habits. The PSG consisted of 14 channel
continuous polygraphic recording from surface leads for 2
electro-encephalography, 2 electro-oculography, chin electro-
myography, electro-cardiography, sensors for nasal airﬂow
(thermistor), tracheal sounds (microphone), thoracic and
abdominal respiratory effort (piezo-electric), ﬁnger pulse oxim-
eter, leg movements, body position and light.
Data obtained from this study were
– Apnea index (AI): Complete cessation of airﬂow breathing
at the nostrils and mouth for at least 10 s or longer.
– Hypopnea index (HI): Decrease in rate and depth of breath-
ing by 50% for 10 s or longer.
– Apnea-hypopnea index (AHI): Average number of apnea
and hypopnea per hour of sleep.OSA is diagnosed if AHI
is 5 or more [20].
Statistical analysis was done using ‘Statistical Package for
Social Science (SPSS) program version 21 (SPSS Inc., Chicago,
IL, USA). Data were expressed as Mean ± SD for quantita-
tive parametric measures. Comparison between two indepen-
dent mean groups for parametric data was performed using
Student’s t-test. Pearson correlation coefﬁcient (r) was used
to test correlation between two quantitative variables. In all
tests if p value >0.05: non-signiﬁcant, if <0.05: signiﬁcant
and if <0.001: highly signiﬁcant.3. Results
This study included 30 female patients with RA; their ages ran-
ged from 30 to 50 years (mean 40.33 ± 6.22). The disease
duration ranged from 3–12 years (mean 6.0 ± 2.82). BMI of
the patients ranged from 18 to 35 kg/m2 (mean 23.8 ± 5.31).
Evaluation of disease activity by DAS28 ranged from 1.58 to
5.4 (mean 3.16 ± 1.01) (Table 1).
Twelve of our patients (40%) had symptoms of OSA.
As regards, laboratory assessment, RF was positive in 13
patients (43.3%). ESR ranged from 35–110 mm/h (meanTable 1 Age, disease duration, body mass index, pulmonary func
patients.
Rheuma
(n= 30)
Age (years) 30–50
Disease duration (years) 3–12
Body mass index 18–35
Pulmonary function tests:
Forced vital capacity (FVC) 56.9–81.
FEV1 45.5–78.
FEV-1/FVC 70–95.4
Polysomnographic data:
Apnea hypopnea index 1–7
FEV-1, forced expiratory volume in ﬁrst second.58.33 ± 13.28) and highly sensitive C-reactive protein
(hsCRP) ranged from 3–8 mg/L (mean 5.3 ± 0.58).
By using DAS28 for assessment of disease activity, there
was 10 active patients (33.3%) with their DAS28 >2.6 (mean
4.26 ± 0.58). While the other 20 patients (66.7%) were inac-
tive (mean 1.88 ± 0.40). Abnormal pulmonary function tests,
were detected in 10 patients (33.3%); all showed an obstructive
pattern (FEV-1/FVC ratio <80), while 20 patients (66.6%)
had normal PFTs.
Fourteen of our patients (46.7%) met the diagnostic criteria
for diagnosis of OSA by polysomnography (AHIP5) while in
the other 16 patients (53.3%) no evidence of OSA was
recorded.
According to the results of polysomnography, the patients
were divided into 2 groups, patients with OSA (n= 14) and
patients without OSA (n= 16). Comparison between both
groups showed that patients with OSA had longer disease dura-
tion (mean 7.0 ± 1.94 years), higher BMI (mean 30.8 ± 2.48)
and higher values of hsCRP (6.7 ± 0.6 mg/L) than patients
with no OSA (mean 4.0 ± 1.72 years, 20.3 ± 1.55 and
4.9 ± 0.3 mg/L respectively) with a highly statistically signiﬁ-
cant difference (p< 0.001). There was a non-signiﬁcant differ-
ence between both groups as regards age, ESR or number of
patients with positive RF (p> 0.05) as shown in Table 2.
As regards pulmonary function tests, of the 10 patients with
obstructive pattern, 5 patients having criteria of OSA consti-
tuting (35.7%) of the patients with OSA (5/14) while the other
5 patients with abnormal PFTs were in the group of patients
without OSA (31.3%) (5/16). So, there was statistically a
non-signiﬁcant difference between patients with and without
OSA as regards patients with abnormal PFTs (p> 0.05) as
shown in Table 2.
Of the 12 symptomatic patients, 66% (8/12) had OSA while
33% of the 18 patients with no sleep complaints (6/18) also
had OSA. In our study, the mean of DAS28 in patients with
OSA was 4.9 ± 1.85, with 7 active patients constituting 50%
(7/14); while the mean DAS28 in patients without OSA was
3.7 ± 1.28 with 3 active patients (3/16, 18.75%). So there
was a statistically signiﬁcant difference between both groups
as regards mean of DAS28 and the number of active cases
(p< 0.05).
The study showed a statistical signiﬁcant correlation
between AHI and BMI, hsCRP and DAS28 (r= 0.45, 0.43
and 0.51, respectively p< 0.05) as shown in Figs. 1–3; whiletion tests and polysomnographic data for rheumatoid arthritis
toid arthritis patients
range (min–max)
Mean ± SD
40.33 ± 6.22
6 ± 2.82
23.8 ± 5.31
1 71.35 ± 8.2
1 62.5 ± 8.75
83.35 ± 4.71
3.66 ± 1.77
Table 2 Comparison between RA patients with and without OSA as regards demographic, clinical, laboratory and pulmonary
function data.
RA patients (n= 30) Sig
With OSA (n= 14) Without OSA (n= 16)
Age (years) 41.2 ± 5.11 39.9 ± 6.6 p> 0.05
Disease duration (years) 7 ± 1.94 4.0 ± 1.72 p< 0.001 (HS)
Body mass index 30.8 ± 2.48 20.3 ± 1.55 p< 0.001 (HS)
ESR (mm/h) 54.34 ± 10.7 58.11 ± 12.9 p> 0.05
hsCRP (mg/L) 6.7 ± 0.6 4.9 ± 0.3 p< 0.001 (HS)
Active cases N (%) 7 (50) 3 (18.75) p< 0.05 (S.)
Abnormal PFT N (%) 5 (35.7) 5 (31.3) p> 0.05
Positive RF N (%) 6 (42.9) 7(43.8) p> 0.05
OSA, obstructive sleep apnea; ESR, erythrocyte sedimentation rate; hsCRP, highly sensitive C reactive protein; RF, rheumatoid factor; S,
signiﬁcant; HS, highly signiﬁcant.
Figure 1 Correlation between apnea-hypopnea index (AHI) and body mass index (BMI) in rheumatoid arthritis patients with
obstructive sleep apnea (OSA).
Figure 2 Correlation between apnea-hypopnea index (AHI) and highly sensitive C reactive protein (hs CRP) in rheumatoid arthritis
patients with obstructive sleep apnea (OSA).
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FEV-1/FVC ratio (r = 0.102, p> 0.05).4. Discussion
Given that disturbed sleep is a well-documented symptom of
RA, sleep is an important consideration in addressing theirhealth and well-being [21]. Most of our knowledge about sleep
problems in RA depends on subjective self-report studies
[22–24]. Except for few polysomnographic studies, there had
been no large quantitative studies of OSA in RA [6,25,26].
So the aim of this work was to assess obstructive sleep apnea
(OSA) as one of common primary sleep disorders in patients
with rheumatoid arthritis (RA) and study its correlation to dis-
ease activity and pulmonary function tests.
Figure 3 Correlation between apnea-hypopnea (AHI) and disease activity score 28 (DAS 28) in rheumatoid arthritis patients with
obstructive sleep apnea (OSA).
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In 2003, Shimizu and his colleagues [25] conducted polysom-
nography evaluations in 96 consecutive Japanese RA patients
(84% women). Remarkably, 53% of this cohort was found to
have OSA by international standards of AHI P5.0. They
hypothesized that patients of Asian heritage have a higher rate
of OSA, possibly due to cephalometric characteristics, but the
expected prevalence in Japan would not be 53% [27]. Another
pilot study conducted by Holman in 2004 [26] reported OSA in
45% of men with a connective tissue disease [RA, systemic
lupus erythematosus (SLE), ankylosing spondylitis (AS) and
psoriatic arthritis]. This is nearly in agreement to our results
although all our cases were females. In a recent polysomnogra-
phy evaluation of 25 RA patients, Gjevre and his colleagues [6]
recorded higher percentage (68%) of RA patients with OSA.
The high mean BMI of their study population (29.65 ± 5.57)
may have contributed to the increased prevalence of OSA
observed in their participants compared with other results.
These ﬁndings have implications regarding the potential
contribution of OSA in rheumatologic-associated morbidities
[28] in RA patients. OSA has been linked to inﬂammatory,
coagulation, and endothelial changes, which can also be found
in patients with RA and possibly suggest common underlying
pathological mechanisms [29]. It has been suggested that the
autonomic response to chronic OSA accounts for much of
the increased cardiovascular disease (CVD) risk [30]. OSA is
a potent and often forgotten cause of autonomic arousal
[31]. Excessive sympathetic tone with noradrenergic activation
during hypoxia and apnea may affect systemic vascular tone,
metabolic and immunologic homeostasis through central and
peripheral mechanisms. These autonomic abnormalities occur
even when patients are awake and not hypoxic. An increased
risk of sudden death in RA also raises concern for untreated
OSA due to the impact of dysautonomia on arrhythmia [32].
In this study 33% of asymptomatic patients had OSA; this
suggests that OSA may be under recognized in RA patients.
There has been increasing recognition that OSA in women
may differ symptomatically [33]. These differences may
contribute to underestimation of OSA in women. As many
rheumatological disorders affect a higher proportion of
women than men, this concern may be relevant for clinical
rheumatologists who have the best opportunity to identify
such a concurrent disease within their patient populations. Inthe study of Gjevre JA [6] higher percentage of asymptomatic
RA patients (60%) had OSA. This can be explained by the
higher percentage of OSA in their study compared to our
study.
It is of interest that we recorded higher levels of hsCRP in
RA patients with OSA. In consistent to our study, several
works have demonstrated increased hsCRP values among
OSA patients [34–36]. The postulated mechanism of the asso-
ciation between OSA and hsCRP is complex. OSA may have
the effects of hypoxemia, reoxygenation, hypercapnia, and
arousals which activate systemic inﬂammation with the pro-
duction of CRP [37]. So co-existence of OSA in RA may inﬂu-
ence the levels of circulating inﬂammatory markers and
mediators in these patients [5]. However, more researches are
needed also to elucidate these ﬁndings.
In this study we did not ﬁnd a signiﬁcant correlation
between OSA and obstructive pattern diagnosed by PFTs in
RA patients. The association between OSA and obstructive
airway disease (OAD) has been investigated. However, so far
the data available show conﬂicting results. Our results are in
agreement with those of the study conducted by Sharma
et al. [38]; while a negative association between PFTs and
OSA was recorded in another study [39] on asthmatic patients.
Some of the mechanisms that may link OSA with obstructive
airway disease include increased parasympathetic tone during
apnea, hypoxemia-related reﬂex bronchoconstriction, irrita-
tion of upper airway neural receptors, altered nocturnal neuro-
hormonal secretion, and increased inﬂammatory mediators
[40]. Corticosteroids may also contribute to OSA by causing
upper airway myopathy [41]. However, Sharma and his col-
leagues [37] explained lack of association in their study that
if there is a link between OSA and OAD, it appears not to
be mediated via airway obstruction per se. It would be interest-
ing to speculate other possible mechanistic links. The OAD
group had higher BMI and larger neck circumference com-
pared to general population and the link could be attributed
to obesity [37]. Further investigation into all these mechanisms
is clearly needed.
Disease activity, as represented by DAS28 was greater in
RA patients with OSA. This is in agreement with the study
of Gjevre and colleagues [6] who recorded a greater RA activ-
ity represented by RADAI score in patients with OSA. These
observations reinforce the concept of a relationship between
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in patients with rheumatic diseases [14]. Also RA patients with
OSA had longer disease duration and these data indicate that
chronic illness plays an important role in disturbed sleep [6].
Interpretation of the present ﬁndings requires consideration
of several limitations. First, the sample population was mainly
composed of female patients consistent with the increased
prevalence of RA in females. Hence, conclusions about the
generalizability of these ﬁndings to males cannot be made.
Also, the sample size limited our ability to apply a regression
analysis in order to identify independent predictors for speciﬁc
PSG ﬁndings. Finally, we have not been able to compare sleep
questionnaire outcomes and PSG ﬁndings. Indeed, additional
analyses are needed to examine the associations between sub-
jective and objective measures of sleep disturbance in RA
patients.
It is not expected that rheumatologists would diagnose and
treat OSA; however, many symptoms of, or risks for, OSA
may be picked up during rheumatological review. A high index
of suspicion may facilitate recognition of possible OSA.
Utilization of a simple screening questionnaire for OSA or
daytime somnolence may be of additional beneﬁt. Referral
to a dedicated sleep clinic for further diagnostic assessment
and therapy as required would be appropriate [14]. Cost con-
siderations, mobility restriction and pain may limit evaluation
of OSA using in laboratory PSG in RA patients. However, It is
important to emphasize that the alternative sleep logs/diaries
and questionnaires that assess various aspects of sleep repre-
sent perceptive rather than objective sleep disturbance and
may be better indicators of patient perception of sleep distur-
bance than reﬂecting true, quantitative sleep abnormalities
[24].
So a study of OSA in patients with RA may offer additional
insight into why these patients are more apt to develop CVD.
Therefore, treatment for co-existing OSA in patients with RA
may prove beneﬁcial in terms of future cardiovascular and
respiratory morbidity, as well as potentially improving mea-
sures of fatigue, pain and inﬂammatory markers [21]. More
researches are needed also to elucidate the impact of OSA
on measures of therapeutic response to RA therapies and to
clarify if anti-TNF therapy alter sleep disturbance or if OSA
contributes to poor response to anti-TNF therapy in RA
patients [42,43].
In conclusion, OSA is commonly associated with patients
with RA. These ﬁndings possibly suggest common underlying
pathological mechanisms which may be linked to chronic
inﬂammation. Co-existence of OSA in RA patients may inﬂu-
ence the disease activity and the level of circulating inﬂamma-
tory markers in these patients. Considering diagnosis and
treatment of this sleep disorder in RA patients may help in
improved clinical care, better prognosis and avoid rheuma-
toid-associated morbidities.
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